Corvus Pharmaceuticals, Inc , a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.
infoCorvus Pharmaceuticals is a micro cap stock with a total market cap of 118.49M.
infoThey trade on the NASDAQ and had their IPO 7 years and 5 months ago.
infoCorvus Pharmaceuticals currently employs 29 people.
infoAs of Wednesday, Aug 23 2023, Corvus Pharmaceuticals’s share price is $2.32.
News Relating to Corvus Pharmaceuticals
Seeking Alpha
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2023 Earnings Call Transcript
Tuesday Aug 08 2023 at 21:57
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2023 Earnings Call Transcript August 8, 2023 4:30 PM ET Company Participants Zack Kubow – IR-Real Chemistry Leiv Lea – CFO Richard Miller – CEO Conference Call Participants Roger Song – Jefferies Aydin Huseynov – Ladenburg Thalmann Rosemary Li – Cantor Fitzgerald Jeff Jones – Oppenheimer Operator Thank you for standing by. This is the conference operator.
GlobeNewsWire
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
Tuesday Aug 01 2023 at 08:30
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
PennyStocks
3 Hot Penny Stocks To Watch Before Next Week
Wednesday Jun 07 2023 at 14:19
Penny stocks typically trade for less than $5 and generally belong to small companies often overlooked by mainstream investors. Yet, for those willing to navigate the inherent risks, these cheap stocks can offer a world of potential.
GlobeNewsWire
Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
Wednesday May 31 2023 at 08:30
BURLINGAME, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer of Corvus, will conduct one-on-one meetings with investors and present a corporate overview at the Jefferies Healthcare Conference, which is being held in New York from June 7-9. The presentation will be on Wednesday, June 7, 2023 at 9:30 am ET.
InvestorPlace
3 High-Potential Penny Stocks to Buy Now
Wednesday May 31 2023 at 08:11
When it comes to penny stocks to buy now, be aware of the risks. While some of these little guys can rocket, some will be duds, which can wipe out your account.
GlobeNewsWire
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
Wednesday May 17 2023 at 09:00
BURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818, the Company’s ITK inhibitor, at the International Conference on Malignant Lymphoma (ICML) meeting, which is taking place June 13-17, 2023 in Lugano, Switzerland.
Seeking Alpha
Corvus Pharmaceuticals: Targeting $1 Billion/Year U.S. T-Cell Lymphoma Market
Friday May 12 2023 at 16:25
Additional Phase 1b data for CPI-818 in T cell lymphoma is expected in this quarter. Phase 2 data for Ciforadenant is expected this year.
InvestorPlace
The 3 Best Biotech Stocks Under $1 to Buy for April
Tuesday Apr 04 2023 at 20:21
Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are always risky — especially some of the best biotech stocks under $1 – and should oftentimes be avoided.
Seeking Alpha
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2022 Earnings Call Transcript
Tuesday Mar 28 2023 at 22:55
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2022 Earnings Conference Call March 27, 2023 4:30 PM ET Company Participants Zack Kubow – Investor Relations-Real Chemistry Leiv Lea – Chief Financial Officer Richard Miller – Co-Founder, President & Chief Executive Officer James Rosenbaum – Senior Vice President-Research Conference Call Participants Mara Goldstein – Mizuho Roger Song – Jefferies Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Fourth Quarter and Full Year 2022 Business Update and Financial Results Conference Call.
GlobeNewsWire
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023
Tuesday Mar 21 2023 at 16:05
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
GlobeNewsWire
Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting
Tuesday Mar 14 2023 at 16:35
Preclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad potential across a range of oncology and immune diseases Preclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad potential across a range of oncology and immune diseases
GlobeNewsWire
Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022
Monday Dec 05 2022 at 08:30
Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PT Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PT
Seeking Alpha
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2022 Earnings Call Transcript
Sunday Nov 06 2022 at 06:39
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Zack Kubow – Investor Relations-Real Chemistry Leiv Lea – Chief Financial Officer Richard Miller – Co-Founder, President & Chief Executive Officer James Rosenbaum – Senior Vice President-Research Conference Call Participants Jerry Gong – Mizuho Securities Roger Song – Jefferies Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2022 Business Update and Financial Results Conference Call.
GlobeNewsWire
Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
Thursday Nov 03 2022 at 09:52
Company to host conference call and webcast on December 12, 2022 at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast on December 12, 2022 at 4:30 pm ET / 1:30 pm PT
GlobeNewsWire
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022
Thursday Oct 27 2022 at 16:05
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
GlobeNewsWire
Corvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Tuesday Sep 06 2022 at 16:05
BURLINGAME, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference, which is taking place September 12-14, 2022. The Company will conduct one-on-one meetings with investors at this conference and a pre-recorded corporate overview presentation by Richard A. Miller, M.D., president and chief executive officer of Corvus, will be available to play on-demand starting at 7:00 am ET on September 12.
Zacks Investment Research
Corvus (CRVS) Moves to Buy: Rationale Behind the Upgrade
Thursday Aug 11 2022 at 13:33
Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Seeking Alpha
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2022 Results – Earnings Call Transcript
Monday Aug 08 2022 at 20:21
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Leiv Lea – Chief Financial Officer Richard Miller – Chief Executive Officer James Rosenbaum – Senior President of Research Conference Call Participants Sean Lee – H.C. Wainwright Operator Good afternoon, and welcome to the Corvus Pharmaceutical Second Quarter 2022 Earnings Conference Call.
PennyStocks
Best Penny Stocks To Watch In April? 3 Insiders Are Buying Now
Monday Apr 04 2022 at 13:22
Penny stocks insiders are buying right now. The post Best Penny Stocks To Watch In April?
Seeking Alpha
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2021 Results – Earnings Call Transcript
Thursday Mar 10 2022 at 19:34
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2021 Results – Earnings Call Transcript
GlobeNewsWire
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
Thursday Mar 03 2022 at 16:30
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
PennyStocks
5 Penny Stocks To Watch For November With Potential Biotech Catalysts
Sunday Oct 31 2021 at 10:30
Biotech penny stocks to watch with upcoming events this week. The post 5 Penny Stocks To Watch For November With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
Hot Penny Stocks to Buy This Week? 3 For Your October Watchlist
Monday Oct 11 2021 at 16:33
Making a list of penny stocks to buy in October? Check these three out The post Hot Penny Stocks to Buy This Week?
Zacks Investment Research
4 Buy-Ranked Stocks that Soared Over 20% in the Past Week
Tuesday Sep 28 2021 at 16:10
The market remains on its toes as investors digest the ton of information hitting us about now.
Seeking Alpha
Corvus Pharmaceuticals: More Than A CD73 Sympathy Play
Thursday Sep 23 2021 at 12:18
Shares rose by 135% on Friday alone, but as of Wednesday have still lost half their value since 2017. Additionally, current enterprise value is still around $260 million.
The Motley Fool
Why Corvus Pharmaceuticals Stock Is Down Today
Wednesday Sep 22 2021 at 15:45
Profit taking appears to be in full effect today with this small-cap biotech.
GlobeNewsWire
Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease
Wednesday Sep 22 2021 at 06:00
Announces results published online in medRxiv in 40 patients from COVID-19 randomized controlled study, which showed primary and secondary endpoints trend toward more favorable outcome for mupadolimab treated patients vs. placebo
Zacks Investment Research
Implied Volatility Surging for Corvus Pharmaceuticals (CRVS) Stock Options
Monday Sep 20 2021 at 09:57
Investors need to pay close attention to Corvus Pharmaceuticals (CRVS) stock based on the movements in the options market lately.
Pulse2
CRVS Stock: The Momentum Continues Today
Monday Sep 20 2021 at 08:12
The stock price of Corvus Pharmaceuticals Inc (NASDAQ: CRVS) increased 135.4% in the previous trading session and the momentum continues today. This is why it happened.
PennyStocks
Best Penny Stocks to Buy Right Now? 3 You Need to Know About
Friday Sep 17 2021 at 12:40
These penny stocks shot up today, are they worth watching or not? The post Best Penny Stocks to Buy Right Now?
Corvus Pharmaceuticals Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Corvus Pharmaceuticals’s Altman Z-score is -0.56 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Corvus Pharmaceuticals Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has bought $24.50K of common stock in Corvus Pharmaceuticals on the stock market with no insider selling.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Corvus Pharmaceuticals’s Income Quality of 0.6 is lower than its Industry Group of 0.69 (-13.0% lower)
Corvus Pharmaceuticals’s Income Quality of 0.6 is lower than its Major Industry Group of 0.71 (-15.5% lower)
Corvus Pharmaceuticals’s Income Quality of 0.6 is lower than its Sector of 0.75 (-20.0% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Corvus Pharmaceuticals’s Current Ratio of 4.82 is in line with its Industry Group of 4.76 (1.3% greater)
Corvus Pharmaceuticals’s Current Ratio of 4.82 is greater than its Major Industry Group of 4.32 (11.6% greater)
Corvus Pharmaceuticals’s Current Ratio of 4.82 is greater than its Sector of 2.6 (85.4% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-2.57 & -1.27)
Cannot compare a negative PE Ratio (-2.57 & -1.1)
Cannot compare a negative PE Ratio (-2.57 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Corvus Pharmaceuticals’s PB Ratio of 2.39 is greater than its Industry Group of 1.34 (78.4% greater)
Corvus Pharmaceuticals’s PB Ratio of 2.39 is greater than its Major Industry Group of 1.4 (70.7% greater)
Corvus Pharmaceuticals’s PB Ratio of 2.39 is greater than its Sector of 1.62 (47.5% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Corvus Pharmaceuticals’s ROE of -0.93 is lower than its Industry Group of -0.44 (-111.4% lower)
Corvus Pharmaceuticals’s ROE of -0.93 is lower than its Major Industry Group of -0.38 (-144.7% lower)
Corvus Pharmaceuticals’s ROE of -0.93 is lower than its Sector of -0.03 (-3000.0% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Corvus Pharmaceuticals’s ROCE of -0.6 is lower than its Industry Group of -0.42 (-42.9% lower)
Corvus Pharmaceuticals’s ROCE of -0.6 is lower than its Major Industry Group of -0.37 (-62.2% lower)
Corvus Pharmaceuticals’s ROCE of -0.6 is lower than its Sector of -0.04 (-1400.0% lower)
Derived from SEC.GOV filing dataopen_in_new